Lentitek Secures £700k Funding to Expand Cancer Therapy Access

Lentitek Ltd, an Edinburgh-based biotechnology firm, has successfully raised £700,000 in private funding to advance its mission of making cancer therapies more accessible. This latest influx of capital, led by Scottish angel investment syndicate Equity Gap, follows a £300,000 grant from Innovate UK, raising the company’s total half-year funding to £1 million. Lentitek is forefronting the development of lentiviral vectors, vital for the administration of pioneering CAR-T cell and gene therapies, which could dramatically alter treatments for cancer and genetic disorders. Existing investors such as Gabriel-IS, Apollo Informal Investment, and Scottish Enterprise contributed to the funding alongside other private investors. Managing Director Fraser Lusty of Equity Gap underscored the strategic value of supporting such breakthrough technologies, which have potential implications for millions affected by cancer in the UK. CEO Adam Inche sees the investment as a strong endorsement of Lentitek's technological progress and potential. The firm has also fortified evaluation agreements with key contract manufacturing firms and aims to broaden partnerships with leading therapeutic developers to confront global healthcare challenges effectively.